|
1
|
Razak AR, Siu LL, Liu FF, et al:
Nasopharyngeal carcinoma: the next challenges. Eur J Cancer.
46:1967–1978. 2010.
|
|
2
|
Yu MC and Yuan JM: Epidemiology of
nasopharyngeal carcinoma. Semin Cancer Biol. 12:421–429. 2002.
|
|
3
|
Cao XP, Lu TX, Ye WJ and Cui NJ:
Prospective study on long-term efficacy of external plus
intracavitary radiotherapy on stage I–II nasopharyngeal carcinoma.
Ai Zheng. 26:204–207. 2007.(In Chinese).
|
|
4
|
Chen Y, Sun Y, Liang SB, et al: Progress
report of a randomized trial comparing long-term survival and late
toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy
versus radiotherapy alone in patients with stage III to IVB
nasopharyngeal carcinoma from endemic regions of China. Cancer.
119:2230–2238. 2013.
|
|
5
|
Chan KH, Gu YL, Ng F, et al: EBV specific
antibody-based and DNA-based assays in serologic diagnosis of
nasopharyngeal carcinoma. Int J Cancer. 105:706–709. 2003.
|
|
6
|
Low WK, Leong JL, Goh YH and Fong KW:
Diagnostic value of Epstein-Barr viral serology in nasopharyngeal
carcinoma. Otolaryngol Head Neck Surg. 123:505–507. 2000.
|
|
7
|
Tsang RK, Vlantis AC, Ho RW, et al:
Sensitivity and specificity of Epstein-Barr virus IGA titer in the
diagnosis of nasopharyngeal carcinoma: a three-year institutional
review. Head Neck. 26:598–602. 2004.
|
|
8
|
Gallagher A, Armstrong AA, MacKenzie J, et
al: Detection of Epstein-Barr virus (EBV) genomes in the serum of
patients with EBV-associated Hodgkin’s disease. Int J Cancer.
84:442–448. 1999.
|
|
9
|
Lei KI, Chan LY, Chan WY, Johnson PJ and
Lo YM: Diagnostic and prognostic implications of circulating
cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.
Clin Cancer Res. 8:29–34. 2002.
|
|
10
|
Chapman C, Murray A, Chakrabarti J, et al:
Autoantibodies in breast cancer: their use as an aid to early
diagnosis. Ann Oncol. 18:868–873. 2007.
|
|
11
|
Boyle P, Chapman CJ, Holdenrieder S, et
al: Clinical validation of an autoantibody test for lung cancer.
Ann Oncol. 22:383–389. 2011.
|
|
12
|
Chang W, Wu L, Cao F, et al: Development
of autoantibody signatures as biomarkers for early detection of
colorectal carcinoma. Clin Cancer Res. 17:5715–5724. 2011.
|
|
13
|
Zayakin P, Ancāns G, Siliņa K, et al:
Tumor-associated autoantibody signature for the early detection of
gastric cancer. Int J Cancer. 132:137–147. 2013.
|
|
14
|
Liu H, Zhang J, Wang S, et al: Screening
of autoantibodies as potential biomarkers for hepatocellular
carcinoma by using T7 phase display system. Cancer Epidemiol.
36:82–88. 2012.
|
|
15
|
Tong YQ, Liu B, Huang J, et al: BMI-1
autoantibody in serum as a new potential biomarker of
nasopharyngeal carcinoma. Cancer Biol Ther. 7:340–344. 2008.
|
|
16
|
Brass N, Rácz A, Bauer C, et al: Role of
amplified genes in the production of autoantibodies. Blood.
93:2158–2166. 1999.
|
|
17
|
Jäger D, Stockert E, Güre AO, et al:
Identification of a tissue-specific putative transcription factor
in breast tissue by serological screening of a breast cancer
library. Cancer Res. 61:2055–2061. 2001.
|
|
18
|
Tan EM: Autoantibodies as reporters
identifying aberrant cellular mechanisms in tumorigenesis. J Clin
Invest. 108:1411–1415. 2001.
|
|
19
|
Finn OJ: Immune response as a biomarker
for cancer detection and a lot more. N Engl J Med. 353:1288–1290.
2005.
|
|
20
|
Qiu J, Choi G, Li L, et al: Occurrence of
autoantibodies to annexin I, 14-3-3 theta and LAMR1 in
prediagnostic lung cancer sera. J Clin Oncol. 26:5060–5066.
2008.
|
|
21
|
Robbins PF, Morgan RA, Feldman SA, et al:
Tumor regression in patients with metastatic synovial cell sarcoma
and melanoma using genetically engineered lymphocytes reactive with
NY-ESO-1. J Clin Oncol. 29:917–924. 2011.
|
|
22
|
Jäger E, Nagata Y, Gnjatic S, et al:
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral
and cellular immune responses. Proc Natl Acad Sci USA.
97:4760–4765. 2000.
|
|
23
|
Gnjatic S, Nishikawa H, Jungbluth AA, et
al: NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer
Res. 95:1–30. 2006.
|
|
24
|
Chapman CJ, Murray A, McElveen JE, et al:
Autoantibodies in lung cancer: possibilities for early detection
and subsequent cure. Thorax. 63:228–233. 2008.
|
|
25
|
Gati A, Lajmi N, Derouiche A, et al:
NY-ESO-1 expression and immunogenicity in prostate cancer patients.
Tunis Med. 89:779–783. 2011.
|
|
26
|
Chen L, Mao YP, Xie FY, et al: The seventh
edition of the UICC/AJCC staging system for nasopharyngeal
carcinoma is prognostically useful for patients treated with
intensity-modulated radiotherapy from an endemic area in China.
Radiother Oncol. 104:331–337. 2012.
|
|
27
|
Fang Qiang-Ji, Hu Liang-Ping and Zhao
Nai-Qing: Binomial distribution. Statistical Methods for Biomedical
Research. 1st edition. Higher Education Press; Beijing: pp.
462007
|
|
28
|
Chapman CJ, Thorpe AJ, Murray A, et al:
Immunobiomarkers in small cell lung cancer: potential early cancer
signals. Clin Cancer Res. 17:1474–1480. 2011.
|
|
29
|
Rodolfo M, Luksch R, Stockert E, et al:
Antigen-specific immunity in neuroblastoma patients: antibody and
T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res.
63:6948–6955. 2003.
|
|
30
|
Zhong L, Coe SP, Stromberg AJ, et al:
Profiling tumor-associated antibodies for early detection of
non-small cell lung cancer. J Thorac Oncol. 1:513–519. 2006.
|
|
31
|
Fernández Madrid F: Autoantibodies in
breast cancer sera: candidate biomarkers and reporters of
tumorigenesis. Cancer Lett. 230:187–198. 2005.
|
|
32
|
Türeci O, Mack U, Luxemburger U, et al:
Humoral immune responses of lung cancer patients against tumor
antigen NY-ESO-1. Cancer Lett. 236:64–71. 2006.
|
|
33
|
Chang KP, Hao SP, Chang JH, et al:
Macrophage inflammatory protein-3alpha is a novel serum marker for
nasopharyngeal carcinoma detection and prediction of treatment
outcomes. Clin Cancer Res. 14:6979–6987. 2008.
|
